Clinical Trial Update: A Study Evaluating the Safety and Efficacy of Atezolizumab in Combination With Obinutuzumab Plus Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating atezolizumab with obinutuzumab and lenalidomide for relapsed or refractory follicular lymphoma has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma

Drugs mentioned

• Atezolizumab (atezolizumab)
• Lenalidomide (lenalidomide)
• Obinutuzumab (obinutuzumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Lymphoma, Follicular | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2019-12-30